[No standalone website (unbranded, no questionnaire)] A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness of Adalimumab Introduction Compared With Methotrexate Dose Escalation (CONTROL)

How to apply

Determine if a study site for this clinical trial is near you. Contact the study to apply.

Find a Study Site

Study’s contact

Call center

+1 347-752-4044

Email address

clinicaltrials@cellectis.com

Condition

Chimeric Antigen Receptor T-Cell (CART-T) Therapy Allogeneic,Relapsed/Refractory Multiple Myeloma,Transcription Activator-Like Effector Nuclease (TALEN)

Treatment type

Interventional

Investigational product

UCARTCS1A

Phase

Phase 1

Sponsor

Cellectis S.A.

ClinicalTrials.gov identifier

NCT04142619

Study number

UCARTCS1A_01

Understanding clinical trials

Get answers to your questions about clinical trials.

About the study

This is a Phase I, FIH, open-label, dose escalation study evaluating Safety and Efficacy of UCART targeting CS1 in patients with Relapsed or Refractory Multiple Myeloma (MM). The purpose of this study is to evaluate the safety and clinical activity of UCARTCS1A and to determine the Maximum Tolerated Dose (MTD).

Who can take part?

You may be eligible to participate in the study if you meet the following criteria:

Inclusion criteria

  1. Patients with confirmed diagnosis of active multiple myeloma (as defined by International Myeloma Working Group [IMWG] criteria) who have relapsed/refractory disease after and have received at least 3 prior lines of prior therapy.
  2. Eastern Cooperative Oncology Group Performance Status of 0 or 1;
  3. No previous treatment with investigational gene targeting CS1 or chimeric antigen receptor therapy targeting CS1
  4. Adequate organ function, including bone marrow, renal, hepatic, pulmonary, and cardiac function based on the last assessment performed within the screening period.
  5. Other criteria may apply.
Exclusion criteria

  1. Previous treatment with investigational gene therapy targeting CS1 or chimeric antigen receptor therapy targeting CS1;
  2. Any cellular therapy (other than autologous or allogenic HSCT) within 60 days prior to enrollment;
  3. Prior treatment with rituximab or other anti-CD20 therapy within 3 months
  4. Any known active or uncontrolled infection
  5. Autologous hematopoietic stem cell transplantation (HSCT) within 12 weeks prior to enrollment; any cellular therapy (other than autologous) within 60 days prior to enrollment; prior allogeneic HSCT.
  6. Seropositive for Hepatitis C virus or positive for Hepatitis B surface antigen or core antibody.
  7. Presence of active and clinically relevant central nervous system disorder, such as epilepsy, generalized seizure disorder, paresis, aphasia, stroke, severe brain injury, dementia, Parkinson's disease, cerebellar disease, or organic brain syndrome.

For a full list of inclusion/exclusion criteria, please visit ClinicalTrials.gov

Study locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to apply

Determine if a study site for this clinical trial is near you. Contact the study to apply.

Find a Study Site